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Cardiovascular disease is a leading cause of death in both humans and dogs. Dilated cardiomyopathy (DCM) accounts for a large
number of these cases, reported to be the third most common form of cardiac disease in humans and the second most common
in dogs. In human studies of DCM there are more than 50 genetic loci associated with the disease. Despite canine DCM having
similar disease progression to human DCM studies into the genetic basis of canine DCM lag far behind those of human DCM. In
this review the aetiology, epidemiology, and clinical characteristics of canine DCM are examined, along with highlighting possible
different subtypes of canine DCM and their potential relevance to human DCM. Finally the current position of genetic research
into canine and humanDCM, including the genetic loci, is identified and the reasons many studies may have failed to find a genetic
association with canine DCM are reviewed.
1. Dilated Cardiomyopathy
Aetiology and Epidemiology
Cardiovascular disease is the fourth most common cause of
death in dogs [1] and one of themost common causes of death
in humans [2]. Dilated cardiomyopathy (DCM) is the second
most prevalent form of heart disease in dogs, accounting for
10% of cardiac diagnoses [3], and is estimated to be the third
most common inherited type of heart disease in humans,
reported to affect 35.6 in 100,000 people, although this is
thought to be an underestimation [4, 5].
Due to the similar nature of DCM in humans and dogs
in terms of disease phenotype and progression, it has been
suggested that canine DCM can act as a model for human
DCM [6]. Conversely, knowledge obtained from the clinical
management of people with DCM may guide improvements
in the clinical care and outcomes of companion animals with
DCM.
Animal models of DCM are useful in providing insights
into the molecular and cellular progression of the disease
and thus lead to potential new treatments [7]. While there
are many animal models where DCM is induced, for exam-
ple [8–11], naturally occurring cases of canine DCM are
also valuable, in particular with regard to natural disease
progression, especially where the underlying cause can be
shown to be similar in dogs and people (e.g., similar genetic
function) [12]. In addition to providing a potential natural
model for human DCM, canine cardiovascular health is an
important issue in its own right. Understanding the disorder
will impact veterinary care, treatment, and prognosis and
may also influence pedigree breeding, health, and welfare.
Here we review the clinically distinct types of canine DCM
and relate these to clinical heterogeneity seen in human
DCM. Furthermorewe provide a review of the known genetic
contributions to DCM and discuss how these factors may
inform future clinical management and breeding strategies in
the dog.
2. Clinical Characteristics of DCM
DCM is characterised by cardiac ventricular chamber
enlargement and systolic dysfunction which often leads
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to congestive heart failure and death [13]. The aetiology
of DCM is complex in that genetic factors, myocardial
ischemia, hypertension, toxins, infections, and metabolic
defects have been implicated in human disease [14]. Both
human and canine DCM have a number of phases of
progression starting with a long asymptomatic period before
clinical signs appear [6, 15]. During this asymptomatic
period, no functional changes in cardiac tissue have yet
been reported, but it is possible that the underlying causes
(e.g., genetic factors, toxins, and infections) are already
initiating the disease [6]. During the next stage, there are
again no reported outward clinical signs and the individual
usually appears to be healthy, but cardiovascular electrical
and morphological changes can be observed [6, 15–17].
Cardiovascular electrical changes may be detected using
Holter monitoring for 24 hours, with individuals that go
on to develop canine DCM often displaying ventricular
arrhythmias [18]. Echocardiography can identify individuals
that have an enlarged left ventricle which ultimately leads
to symptomatic canine DCM [18]. Due to the apparently
asymptomatic nature of this stage it is often termed the occult
or preclinical stage and can last for several years in dogs
[6, 17, 18]. In the final stage of DCM patients present with
clinical signs of heart failure, commonly including cough,
depression, dyspnoea, weight loss, and syncope, the indi-
vidual requires treatment for heart failure, but progno-
sis is often poor [6, 19]. In humans, mortality 10 years
following diagnosis is roughly 40%, although there is a
wide variation with some individuals remaining asymp-
tomatic, conversely many individuals suffer from sudden
death [20]. Dogs also have significantly shortened lifespan
following diagnosis, mean survival time following diag-
nosis, usually at the point of developing overt clinical
symptoms, being 34 weeks, although, similar to humans,
large variations are observed, with some surviving for
several months while others only live for a few weeks
[21–23].
Treatment of DCM in humans is aimed at minimising
the effect of heart failure on the patient and delaying disease
progression [24]. Standard medical treatment for human
DCM consists of ACE inhibitors and 𝛽-blockade, often
with a diuretic agent and, in the latter stages of disease
progression, inotropic agents are frequently prescribed [24,
25]. Heart transplants are often the last resort in treat-
ing human heart disease; however the proportion of heart
transplants in humans due to nonischemic cardiomyopathy,
of which DCM is the second most common form, has
increased to become the leading cause of heart transplant
in recent years: 51% of transplant cases had nonischemic
cardiomyopathy [26]. Canine DCM is treated in a simi-
lar manner to human DCM, in that treatment is aimed
at minimising the effect of heart failure [27]. This treat-
ment usually consists of diuretics, ACE inhibitors, positive
inotropes, and other vasodilators [27, 28]. There is evi-
dence that treatment when preclinical symptoms appear can
increase lifespan, but this requires screening of individuals
for preclinical DCM [29]. Heart transplants and other cardiac
assist devices are not generally available to canine DCM
patients.
2.1. Evidence for Different Types of Canine DCM. Although
dogs within all breeds have the potential to develop DCM,
there are some breeds that are particularly afflicted by DCM
[30]. These include Newfoundlands, St. Bernards, Dober-
man Pinschers, Great Danes, Irish Wolfhounds, Boxers, and
English Cocker Spaniels [3]. While these breeds, as well as
other less frequently affected breeds, can be diagnosed as
having DCM, there is evidence that different breeds may
present with distinct types of DCM. This evidence consists
of differential survival times from diagnosis, histopathology,
inheritance patterns, and age of onset [21, 31–35].
Within canine DCM, two distinct types of histopatholog-
ical variations have been described: “attenuated wavy fibre
type” and “fatty infiltration type” [32]. While this evidence
may be subjective, it adds to the evidence suggesting that
there are different types of canine DCM.The fatty infiltration
type is less subjective and has only been reported in Dober-
man Pinschers, Estrela Mountain Dogs, Great Danes, and
Boxers [32, 36–38]; while the wavy fibre type is more ubiq-
uitous, it does not seem to be restricted to specific breeds and
can also occur in breeds which display the fatty infiltration
type [32, 37]. As the wavy fibre type is found across breeds
and in many individuals, it could be the tissue’s response
to the other processes of DCM. In particular atrophy, or
attenuation, of muscle fibres is a frequent result of processes
that prevent normal contractile ability: contractile ability
is consistently compromised in DCM [19]. The prevalence
and clinical significance of these histopathological variants
remain to be established, although the phenotype can only
be established post mortem and thus is unlikely to be useful
in a clinical setting.
Human DCM is generally inherited in an autosomal
dominant fashion [39], but autosomal recessive, X-linked
recessive, and mitochondrial modes of inheritance have all
been reported [40]. In common with human inheritance
patterns there are several types of inheritance suggested in
canine DCM. These include autosomal recessive [34], X-
linked [33], and the common autosomal dominant inheri-
tance [35, 38]; although often with reduced penetrance, not
all dogs with the DCM genotype will develop the disease
[41, 42]. X-linked and autosomal inheritance patterns show
that the genetic basis of the disease is different. Recessive and
dominant inheritance patterns also suggest the presence of
different mutations leading to DCM and reduced penetrance
indicates that there are likely to be additional factors involved
in the formation of the disease phenotype. These additional
factors may involve additional genes, epigenetic effects, and
environmental effects including, but not limited to, diet,
exercise, stress and toxins, or a combination of any number
of these.
There is a wide variation in the long term prognosis
of canine DCM. Some dogs, with appropriate disease man-
agement, can have a good quality of life for many years
following a DCM diagnosis, whereas others die within weeks
despite medical intervention [21–23]. Within this variation
there are prognosis trends within breeds. Doberman Pin-
schers are a breed with particularly poor prognosis, and
mean time to death (from diagnosis) is in the range of
7.4 to 9.7 weeks [21, 31], while the mean time for other
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breeds is reported to be about four times that at 34
weeks [21]. Great Danes also suffer from a poor prognosis
with Martin et al. [23] finding that they have the lowest
median survival time of breeds included in their analysis,
while Doberman Pinschers had the lowest upper quartile
range.
Age of onset can also affect prognosis. There is a juvenile
form of DCM in Portuguese water dogs, where age of onset
is measured in weeks from birth [43, 44], while in most other
cases age of onset is measured in years [45]. It would seem
from this that DCM in Portuguese water dogs is a distinct
condition. Even within adult canine DCM there is variation
between breeds as to when individuals present with outward
clinical signs. For example, Great Dane mean age of onset
is 4.8 (SD ± 2.3) years [33], which is comparable to Irish
Wolfhound mean age of onset of 4.40 (SD ± 2.03) years [42];
however, Doberman Pinscher’s mean age of onset is in 7.3
years in males and 8.6 years in females [31]. This variation
in mean age of onset could further suggest that there are
different types of canine DCM.
There also appears to be different types of human DCM,
with different inheritance patterns and age of onset reported
[46]. If canine DCM can be appropriately matched to human
DCM in terms of age of onset, inheritance pattern, survival
time, and histopathology, they could provide appropriate
models for each other. In particular some cases of childhood
DCM have been shown to have an autosomal recessive
pattern of inheritance [47], and in this instance the juvenile
DCM observed in Portuguese water dogs [44] could be an
appropriate model.There are currently several types of DCM
identified in humans [39], but additional studies of canine
DCMphenotypes are required to allow appropriatematching
of canine and human DCM categories. Once identified,
knowledge about canine DCM types could benefit current
and future potential treatments and support for both human
and canine DCM patients, in addition to elucidating other
clinically important factors in canine DCM, such as longevity
and prognosis.
2.2. Genomic Research of DCM in Humans. While there are
many implicated causes or risk factors related to developing
DCM and disease progression, genetics is a common one,
with the disease often affecting several individuals within
a family. To date mutations in over 50 genes have been
associated with DCM in humans; however mutations in
the most prevalent DCM related genes only account for
approximately 50% of patients with DCM [39]. Genetic
testing of individuals related toDCMpatients can allow those
that are at high risk of developing DCM to be more closely
monitored [48]. This genetic testing is carried out on a panel
of about 50 loci and more than one locus can be implicated
in the disease [14] suggesting a dose effect, whereby the
more DCM alleles an individual carries, the more severe the
phenotype [39]. Gene penetrance has also been reported to
affect disease expression and severity, and likewise the type
of mutation and the specific gene which is affected often lead
to differing features, age of onset or severity, and prognosis
[49, 50].
Human DCM-associated genes identified to date are
involved in a range of functions but can usually be placed
into one of six functional groups: sarcomeric protein genes,
cytoskeletal protein genes, nuclear envelope protein, desmo-
somal protein genes, calcium/sodium-handling genes, and
transcription factor genes [39]. Cardiac muscle consists of
striated muscle, and the sarcomere is the smallest unit of
contractile muscle within this and thus alterations to this
could lead to heart disease [51]. The cytoskeleton forms the
majority of the cytoplasm, enabling cells to maintain their
shape and facilitating communication within the cell [52, 53].
The nuclear envelope provides a barrier between nucleic acid
synthesis and the rest of the cell but must remain permeable
to allow the cell to function [54], a large number of proteins
within the nuclear envelope have been implicated in chro-
matin organization and gene regulation [55].The desmosome
provides mechanical strength to tissues and potentially has
cell signalling capacity, both of which are essential for cardiac
function [56]. Na+/Ca2+ are important in the contraction
of muscle [57] and as such calcium/sodium-handling genes
are important in maintaining the correct concentration of
Na+/Ca2+ for contraction of the heart. Transcription factors
regulate the rate at which transcription of DNA to mRNA
occurs; this rate is important in controlling the expression of
genes and therefore the amount of a protein produced [58].
The breakdown of any of these functions has the capacity to
lead to disease, including DCM. Table 1 shows the genes with
mutations associated with DCM in humans, including the
group into which the gene falls (where appropriate).
2.3. Genetics of Canine DCM. Canine DCM has often been
used as a model for human DCM, but it is also a major
clinical challenge in companion animals [3, 18, 22, 59]. It is
has been established that, in common with human DCM,
canine DCM frequently has a familial basis [33–35, 42].
Despite this, current understanding of the genetics of canine
DCM is limited, in particular compared to the depth of
genetic information available for human DCM. Indeed it
is only recently that any loci have been associated with
canine DCM [6, 60–62]. Genes associated with canine DCM
are DMD in German short-haired pointers [63], PDK4 in
Doberman Pinschers [60], and STRN in Boxers [62], in
addition to a locus on chromosome 5 inDoberman Pinschers
[6]. Additional polymorphisms on chromosomes 1, 10, 15, 17,
21, and 37 have also been implicated in IrishWolfhounds [61].
There are two methods that have been employed in attempts
to identify genes associatedwith canineDCM, candidate gene
studies, and genome wide association studies (GWAS).
3. Canine Candidate Gene Studies
Candidate gene studies for canine DCM primarily involve
examining genes with variants associated with human DCM
or associated conditions, for example [64–69]. The majority
of canine DCM genetic studies have been of this type;
however, only onemutation associated with canine DCMhas
been identified in this manner, which is that of a deletion
in the Striatin gene in Boxers, a gene previously associated
4 International Journal of Genomics
Table 1: Genes with mutations associated with DCM in humans.
Gene Location/role Reference
ABCC9 Calcium/sodium-handling [81]
ACTC1 Sarcomere & cytoskeleton [82]
ACTN2 Sarcomere & cytoskeleton [83]
ANKRD1 Sarcomere & transcription factor [84]
BAG3 Sarcomere [85–87]
CAV3 Other [88]
CHRM2 Other [89]
CRYAB Cytoskeleton [90]
CSRP3 Sarcomere & cytoskeleton [83]
CTF1 Other [91]
DES Cytoskeleton [92, 93]
DMD Cytoskeleton [94, 95]
DNAJC19 Other [96]
DOLK Other [97]
DSC2 Desmosome [98]
DSG2 Desmosome [99]
DSP Desmosome [100]
EYA4 Other [101]
FHL2 Sarcomere & cytoskeleton [102]
FKTN Cytoskeleton [103]
FKRP Cytoskeleton [104]
FOXD4 Transcription factor [105]
GATAD1 Other [106]
HCG22 Other [107]
HLA-DQB1 Other [108]
HSPB7 Other [109]
ILK Cytoskeleton [110]
LAMA2 Other [111]
LAMA4 Cytoskeleton [110]
LAMP2 Other [112]
LDB3 Sarcomere & cytoskeleton [113]
LMNA Nuclear envelope [114]
MURC Other [115]
MYBPC3 Sarcomere [116, 117]
MYH6 Sarcomere [117, 118]
MYH7 Sarcomere [116]
MYPN Cytoskeleton [119]
NEBL Sarcomere [120]
NEXN Sarcomere [121]
NOS3 Other [122]
PKP2 Desmosome [98]
PLN Calcium/sodium-handling [123]
PRDM16 Transcription factor [124]
PSEN1 Other [125]
PSEN2 Other [125]
RBM20 Other [126]
RYR2 Calcium/sodium-handling [127]
SCN5A Calcium/sodium-handling [128]
Table 1: Continued.
Gene Location/role Reference
SDHA Other [129]
SGCD Cytoskeleton [130]
SYNE1 Nuclear envelope [131]
TAZ Other [132]
TBX20 Transcription factor [133]
TCAP Sarcomere & cytoskeleton [134]
TMPO Nuclear envelope [135]
TNNC1 Sarcomere [117]
TNNI3 Sarcomere [136]
TNNT2 Sarcomere [137]
TPM1 Sarcomere [117]
TXNRD2 Other [138]
TTN Sarcomere & cytoskeleton [139]
VCL Sarcomere & cytoskeleton [140]
ZBTB17 Other [141]
with Boxer arrhythmogenic right ventricular cardiomyopa-
thy using GWAS [62]. All other candidate gene studies have
failed to find an association with canine DCM in the cohort
examined (see Table 2), and unfortunately the small sample
sizes frequently utilised could have limited the power to
detect an association. In addition to small sample sizes in a
number of studies, control (non-DCM cases) dogs have been
limited or have not been appropriate (see Table 2 for exact
numbers). Suitable controls should be breed matched and
over a certain age to ensure that they are unlikely to develop
DCM. Table 2 shows the genes examined for mutations
associated with canine DCM in a variety of breeds, sample
sizes, and control dogs, in the published literature to date.
4. Genome Wide Association Studies (GWAS)
Genome wide association studies are a method of screening
the genomes of many individuals for variants or regions that
are associated with a trait [70]. Some variants will fall within
genes and some outside of genes. When variants associated
with a trait are found outside of genes it can be more difficult
to establish their mode of action.
There have been three GWAS looking for an association
with canine DCM. One of these led to the identification of
a deletion in a splice site of PDK4 associated with DCM in
Doberman Pinschers [60]. A separate GWAS in Doberman
Pinschers revealed a single SNP associated with DCM in a
different location to thePDK4 gene [6].The only otherGWAS
undertaken with regard to canine DCM is that by Philipp et
al. [61] which found one significantly associated SNP and five
suggestively associated SNPs in Irish Wolfhounds. Of all the
loci identified as associated with canine DCM only two are
on the same chromosome, one of the Irish Wolfhound SNPs
and the Striatin genes are both on chromosome 17, but even
these are far apart.This indicates that there may be many loci
involved in the development of canine DCM.
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Figure 1: 𝜒2goodness of fit tests: contingency tables Df = 1, 𝛼 err
prob = 0.05, and power (1 − 𝛽 err prob) = 0.8.
5. The Effects of Multiple Loci on DCM
Thus far in both canine and human genetic DCM studies loci
have only been considered for an association with disease
individually. There have been indications that multiple loci
may influence the development of DCM [6]. In human DCM
where a pannel of more than 50 loci are tested concurrently,
often several loci are implicated. Simpson et al. [71] have
shown theoretically that multiple loci affect the development
of DCM in Doberman Pinschers. While this still requires
valiadation, it is possible that similar effects occur in other
breeds and species.
6. Power to Detect an Association with
Canine DCM
The majority of studies undertaken with the aim of identify-
ing causal genetic variants of canine DCM have only utilised
small samples (5–40 individuals) which is unlikely to be large
enough to detect an effect. To establish appropriate study sizes
and indicate the effect size that can be detected in published
studies G∗Power 3.1.7 Chi-squared goodness of fit tests were
used (using the methods from [72]). This takes known input
parameters, including sample size, and calculates estimated
effect sizes based on assumed power and can be used to
indicate minimum sample size for prescribed power, alpha
error rate, and effect size.This was done to indicateminimum
sample sizes needed to detect various effect sizes (Figure 1).
Published studies that have identified genetic variants
associated with DCM have used sample sizes of 180 [6],
132 [60], and 49 [62]. Assuming these studies had enough
power to identify a positive effect (0.8), the effect sizes of
these variants in these studies are 0.2088, 0.2438, and 0.4002,
respectively, calculated using the sensitivity power analysis
in G∗Power 3.1.7 [72]. These effect sizes, while not large, are
larger than the standard effect size for small effect of 0.1. None
of these variants explain all incidences of DCM, suggesting
that other factors, whichmay be additional genetic variants of
smaller effect, are involved.The sample size required to obtain
a positive result from variants with small effect size (0.1) is
785, a number possibly not obtainable for all breeds but could
be aimed for in future studies. It is likely that earlier studies
concentrated on simple Mendelian recessive, dominant traits
and even a multiplicative risk models where Karlsson &
Lindblad-Toh [73] had suggested that affected and control
groups of 20, 50, and 100, respectively, may suffice. Despite
these suggestions, the authors indicated that higher group
sizes (around 500 samples) would likely provide sufficient
power to map an allele conferring a two-fold risk.
6.1. Discussion of Selected Breeds. While there are many
breeds affected by canine DCM only a few have had genetic
loci identified as associated with the disease. Here we discuss
breeds with adolescent and adult onset DCM associated loci.
The juvenile DCM that Portuguese water dogs develop is not
discussed because it is already considered to be a distinct
condition [34].
6.2. Boxers: Striatin (STRN). The Boxer breed of dog was
developed in the late 1800’s primarily from the now extinct
hunting dog the Bullenbeisser [74]. As with the development
of most modern breeds there is documented evidence of
inbreeding to produce the desired characteristics. In the case
of the boxer this included a mating of a son to his mother,
and following the creation of a breed standard in 1902 it is
likely that usually Boxers will have exclusively been mated
to other Boxers [74]. This limited genetic diversity is likely
to have led to Boxers being prone to developing a number
of diseases including heart disease, of which they frequently
develop both arrhythmogenic right ventricular cardiomyopa-
thy (ARVC) andDCM [62]. Since boxer cardiomyopathy was
described by Harpster [75] there have been several subtypes
described, of the two displaying overt clinical symptoms
these most closely align to human ARVC and DCM [62].
Recently Meurs et al. [62] tested a deletion in the striatin
(STRN) gene for an association with DCM in boxers. This
deletion has previously been associated with ARVC and it
was hypothesised that ARVC and DCM are variants of the
same disease in Boxers and the homozygous genotype leads
to DCM rather than ARVC [62]. They found a significant
association with the deletion in its homozygous form and
DCM, but there were three cases of DCM where there was
no deletion in the gene, thus indicating that there is at least
one more cause of DCM in the breed to be established [62].
6.3. DobermanPinschers: PDK4 andChromosome 5 SNP. The
Doberman Pinscher breed was developed at the end of the
1800’s in Germany [76] when a number of individuals from
established breeds were used to improve various characteris-
tics. According to Gruenig [76] these include the Manchester
terrier, Greyhound, Rottweiler, Gordon Setter, Old English
Sheepdog, Beauceron, Pinscher (probablyGermanPinscher),
Weimaraner, and other less specific breeds such as Mastiff
(possibly Great Dane), Hound, and Sporting dogs. The
development of the breed happened rapidly, over a period of
about 30 years, and since thenDobermanPinschers have only
been bred to Doberman Pinschers [76], leading to a closed
gene pool. Although a number of breeds contributed to the
Doberman Pinscher it is likely that relatively few individuals
of each breed were used likely leading to low genetic diversity.
In addition to relatively few founders there is evidence of
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some individuals contributing a greater number of offspring
to the breeding population than others [76].
Doberman Pinschers can develop a particularly severe
type of DCM with rapid disease progression following the
diagnosis of DCM with mean survival time of less than
10 weeks [21, 31]. Poor survival time following diagnosis
combined with the high prevalence of the disease with
estimates ranging from 45% to 63% means DCM in this
breed is a particular problem for clinicians [59]. Doberman
Pinschers display the fatty infiltration type of histopathology
[32]. Despite these poor statistics, age of onset of clinical signs
is often later than in other commonly affected breeds (7.3
years in males and 8.6 years in females, compared to 4.8 (SD
± 2.3) years inGreat Danes), giving individuals a good quality
of life up until overt DCM clinical signs [31, 77]. Across
age groups there is no difference in clinical signs associated
with DCM between the sexes including echocardiographic
changes, presence and number of ventricular premature
contractions, and overt DCM [59]. Unfortunately, however,
males are more likely to have overt DCM than females with
73.7% of all observed males becoming clinically overt while
only 26.3% of females observed became clinically overt [59].
DCM in Doberman Pinschers appears to be inherited in
an autosomal dominant fashion with equal numbers of males
and females affected,male-male transmission, and themating
of two affected individuals producing unaffected offspring
[35]. There have been two loci identified as associated with
DCM in the breed, a deletion of a splice site in pyruvate
dehydrogenase kinase, isozyme 4 (PDK4), and a SNP on
chromosome 5 [6, 60]. Unfortunately neither of these loci
explains all incidences of DCM, and the PDK4 deletion is not
significantly associated with DCM in a separate Doberman
Pinscher population [78]. There are still additional causes of
DCM to be identified in Doberman Pinschers and the func-
tion of the SNP on chromosome 5 needs to be established.
6.4. German Short-Haired Pointers: Dystrophin (DMD). The
only gene associated with canine DCM in German short-
haired pointers is Dystrophin (DMD) [63]. German short-
haired pointers are not considered a breed particularly
afflicted by heart disease and the deletion was only identified
in two male litter mates [3, 63]. This could be an isolated
case which is unlikely to have implications in other breeds,
particularly as the affected individuals also had skeletal
myopathies, whereas in most cases of canine DCM there are
not any other myopathies present [63].
6.5. Irish Wolfhounds. Although Irish Wolfhounds have a
long history, this includes a period when they were close to
extinction. As part of conserving the breed, Great Danes,
Scottish deerhounds, Borzoi, and Mastiffs were crossed with
the few remaining Irish Wolfhounds [61, 79]. While this will
have introduced some degree of genetic diversity to the breed,
by necessity a large amount of inbreeding will have been
required to retain the IrishWolfhound phenotype and so, like
most modern breeds, genetic diversity is low [80].
Irish Wolfhounds do not usually develop a particularly
severe form of DCM and with appropriate management can
live with the disease for many months or years [22]. Unfor-
tunately, however, the prevalence of heart disease, including
DCM, within the breed is very high, with 41% of individuals
presenting with cardiac abnormalities, of which 58% have
DCM [22]. This high prevalence combined with early onset
of clinical signs at around 4 years old [42] means that DCM
in Irish Wolfhounds is of concern and so identifying genetic
causes of the disease could have a large impact on the health
of breed.
The mode of inheritance of DCM in Irish Wolfhounds
has been shown to be autosomal dominant major gene effect,
but with reduced penetrance indicating that multiple factors
influence disease progression [42]. Of the six SNPs associated
with DCM in Irish Wolfhounds to date, only three lie within
known genes [61]. Further work is therefore required to
establish the functional significance of the alleles and to
confirm the associations with DCM.
7. Conclusions: Impact of Genetics on
Canine DCM
In the short term, the identification of the genetic contribu-
tors to DCM will enable targeted heart monitoring prior to
the onset of clinical signs and clinical management of those
dogs with increased risk of developing DCM. In the longer
term, knowledge of the genetic factors which predispose
to DCM will allow for selective breeding strategies to be
considered andmay identify novel therapeutic and diagnostic
approaches. Individuals likely to develop DCM, identified
through robust genetics, could be removed from breeding
programmes with the ultimate goal of reducing the number
of affected animals within the population and promoting the
long term welfare of the breed. Understanding the genetic
causes may also aid the stratification of distinct clinical
subtypes of DCM.This knowledgemay also permit the devel-
opment of novel DCM management programmes, help to
guide prognosis, and assist with future drug and intervention
research. Furthermore, investigations into causative genes in
canineDCMmayprove beneficial for other species, including
humans. Novel mutations in canine breeds may serve as
candidate genes in affected humans. For these reasons amore
detailed understanding of the genetic basis ofDCM in diverse
dog breeds is now required.
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